NS-2710 explained

NS-2710 (LS-193,970) is an anxiolytic drug with a novel chemical structure, developed by the small pharmaceutical company NeuroSearch. It has similar effects to benzodiazepine drugs, but is structurally distinct and so is classed as a nonbenzodiazepine anxiolytic. NS-2710 is a potent but non-selective partial agonist at GABAA receptors, although with little efficacy at the α1 subtype and more at α2 and α3. It has anxiolytic effects comparable to chlordiazepoxide,[1] and while it is a less potent anticonvulsant than the related drug NS-2664, it has a much longer duration of action, and similarly to other α2/α3-preferring partial agonists produces little sedative effects or physical dependence.[2]

References

  1. Evenden J, Duncan B, Ko T . A comparison of the effects of psychotomimetics and anxiolytics on punished and unpunished responding maintained by fixed interval schedules of food reinforcement in the rat . Behavioural Pharmacology . 17 . 1 . 87–99 . February 2006 . 10.1097/01.fbp.0000189812.77049.e5 . 16377966 . 12424100 .
  2. Mirza NR, Nielsen EØ . Do subtype-selective gamma-aminobutyric acid A receptor modulators have a reduced propensity to induce physical dependence in mice? . The Journal of Pharmacology and Experimental Therapeutics . 316 . 3 . 1378–85 . March 2006 . 16352707 . 10.1124/jpet.105.094474 . 22700422 .